ReviewDiscover oncology2026
Small interfering RNA (siRNA)-based targeting breast cancer therapy.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) poses a substantial impact on the global health landscape, thereby demanding the creation of novel therapeutic approaches aimed at enhancing patient outcomes. The objective of this article is to conduct an analysis of the potential benefits and drawbacks related to the application of siRNA-based therapy in the context of BC, along with its targeting capabilities. This paper commences by highlighting the imperative need for pioneering treatment methodologies in response to the substantial incidence of BC. This section of the article examines the molecular mechanisms underlying small interfering RNA (siRNA), with a particular emphasis on its role in selectively suppressing cancer-associated genes involved in tumor initiation and progression. The efficacy of therapies utilizing siRNA is reliant on the presence of effective delivery mechanisms. The objective of this research is to examine the effectiveness and safety of liposomes, nanoparticles (specifically carbon nanoparticles and metal nanoparticles), as potential vehicles for delivering targeted siRNA. Moreover, the objective of this article is to investigate the potential of siRNA in the context of mitigating drug resistance and augmenting the effectiveness of treatments. Additionally, the study aims to investigate the obstacles related to delivery efficiency, potential immune responses, and the suppression of off-target genes. The present comprehensive literature review concludes with a meticulous examination of the potential transformative effects of siRNA-based therapeutic approaches for BC. The primary objective of this study is to advance the development of enhanced and personalized therapeutic interventions for BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.